emalexbiosciences.com valuation and analysis

Robots.txt Information
Robot Path Permission
GoogleBot / ✔
BingBot / ✔
BaiduSpider / ✔
YandexBot / ✔ 
User-agent: * Disallow: /wp-admin/ Allow: /wp-admin/admin-ajax.php Disallow:
Meta Tags
Title Emalex
Description Latest Developing new treatments for rare and orphan neurological
Keywords N/A
Server Information
WebSite emalexbiosciences faviconemalexbiosciences.com
Host IP 173.254.216.4
Location United States
Related Websites
Site Rank
More to Explore
emalexbiosciences.com Valuation
US$4,973,091
Last updated: 2023-05-01 07:40:49

emalexbiosciences.com has Semrush global rank of 2,128,315. emalexbiosciences.com has an estimated worth of US$ 4,973,091, based on its estimated Ads revenue. emalexbiosciences.com receives approximately 573,819 unique visitors each day. Its web server is located in United States, with IP address 173.254.216.4. According to SiteAdvisor, emalexbiosciences.com is safe to visit.

Traffic & Worth Estimates
Purchase/Sale Value US$4,973,091
Daily Ads Revenue US$4,591
Monthly Ads Revenue US$137,717
Yearly Ads Revenue US$1,652,597
Daily Unique Visitors 38,255
Note: All traffic and earnings values are estimates.
DNS Records
Host Type TTL Data
emalexbiosciences.com. A 299 IP: 173.254.216.4
emalexbiosciences.com. NS 3600 NS Record: ns1.tierra.net.
emalexbiosciences.com. NS 3600 NS Record: ns2.tierra.net.
emalexbiosciences.com. MX 3600 MX Record: 10 us-smtp-inbound-1.mimecast.com.
emalexbiosciences.com. MX 3600 MX Record: 10 us-smtp-inbound-2.mimecast.com.
emalexbiosciences.com. TXT 3600 TXT Record: MS=ms35156541
emalexbiosciences.com. TXT 3600 TXT Record: 0ed1fe018a520ab0f97e7d4ecb96bec4
emalexbiosciences.com. TXT 3600 TXT Record: lnqxc5fd6h6vynfsc4v731tyyw7cgcj4
emalexbiosciences.com. TXT 3600 TXT Record: v=spf1 include:us._netblocks.mimecast.com include:spf.protection.outlook.com -all
HtmlToTextCheckTime:2023-05-01 07:40:49
Menu ABOUT US OUR COMMITMENT LEADERSHIP RESEARCH & DEVELOPMENT THERAPEUTIC FOCUS CLINICAL TRIALS DRUG PIPELINE EXPANDED ACCESS POLICY PATIENT RESOURCES NEWS CONTACT Linkedin Menu ABOUT US OUR COMMITMENT LEADERSHIP RESEARCH & DEVELOPMENT THERAPEUTIC FOCUS CLINICAL TRIALS DRUG PIPELINE EXPANDED ACCESS POLICY PATIENT RESOURCES NEWS CONTACT Linkedin We develop new treatments for central nervous system disorders. We develop new treatments for central nervous system disorders. Emalex is in a late-stage clinical study of a new class of drug for patients with Tourette syndrome who have limited treatment options. OUR COMMITMENT CLINICAL TRIALS DRUG PIPELINE PARTNERSHIPS Latest News Emalex Biosciences Announces First Patient Dosed in Phase 3 Trial of Ecopipam for Tourette Syndrome March 1, 2023 – Enrolled patients will receive medication for up to 24 weeks; 90 sites planned for North America and Europe – CHICAGO, March 1, 2023 – Emalex Biosciences announced that the first patient was dosed in
HTTP Headers
HTTP/1.1 301 Moved Permanently
Content-length: 0
Location: https://emalexbiosciences.com/

HTTP/1.1 200 OK
Date: Sat, 23 Oct 2021 22:37:09 GMT
Server: Apache/2.4.38 (Debian)
X-UA-Compatible: IE=edge
Link: ; rel="https://api.w.org/", ; rel="alternate"; type="application/json", ; rel=shortlink
Content-Type: text/html; charset=UTF-8
emalexbiosciences.com Whois Information
Domain Name: EMALEXBIOSCIENCES.COM
Registry Domain ID: 2248059376_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.domaindiscover.com
Registrar URL: http://tierra.net
Updated Date: 2021-02-20T06:16:04Z
Creation Date: 2018-04-04T20:54:22Z
Registry Expiry Date: 2022-04-04T20:54:22Z
Registrar: DomainSpot LLC
Registrar IANA ID: 86
Registrar Abuse Contact Email: abuse@tierra.net
Registrar Abuse Contact Phone: 858-560-9416
Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited
Name Server: NS1.TIERRA.NET
Name Server: NS2.TIERRA.NET
DNSSEC: unsigned
>>> Last update of whois database: 2021-09-12T07:55:42Z <<<

Copyright © 2022 WebZZ.US 0.0232